{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018036","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.298839+00:00","generated_at":"2026-06-02T18:41:55.266693+00:00","sec_items":["1.01","3.03","3.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PAVmed subsidiary Lucid Diagnostics raises $11.6M in Series B-1 preferred stock offering","bullets":["Lucid Diagnostics, PAVmed's majority-owned subsidiary, raised ~$11.6M via Series B-1 Convertible Preferred Stock.","Sold approx 11,634 shares at $1,000/share to accredited investors; closed May 6, 2024.","Lucid filed Certificate of Designation for Series B-1 Preferred and entered Registration Rights Agreement.","Details are incorporated by reference from Lucid Diagnostics' separate 8-K filed May 7, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018036","json":"https://secwatch.observer/filing/0001493152-24-018036.json","markdown":"https://secwatch.observer/filing/0001493152-24-018036.md","text":"https://secwatch.observer/filing/0001493152-24-018036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224018036/0001493152-24-018036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224018036/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:41:55.266693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ceff8065c294a338ffb4f8a6b11ed0d506d39e8","claim":"PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at approximately $11.6 million (effective 2024-05-01).","evidence_excerpt":"entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors (collectively, the “ Investors ”), which agreements provided for the sale to the Investors of approximately 11,634 shares of Lucid Diagnostics’ newly designated Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share (collectively, the “ Offering ”). The gross proceeds to Lucid Diagnostics of the Offering were approximately $11.6 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224018036/0001493152-24-018036-index.htm","confidence":0.92,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $11.6 million"},{"label":"Effective","value":"2024-05-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}